99-31437. Johnson Matthey, Inc., West Deptford, New Jersey; Notice of Administrative Hearing, Summary of Comments and Objections  

  • [Federal Register Volume 64, Number 232 (Friday, December 3, 1999)]
    [Notices]
    [Page 67936]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 99-31437]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF JUSTICE
    
    Drug Enforcement Administration
    [Docket No. 99-27]
    
    
    Johnson Matthey, Inc., West Deptford, New Jersey; Notice of 
    Administrative Hearing, Summary of Comments and Objections
    
    Notice of Hearing
    
        This Notice of Administrative Hearing, Summary of Comments and 
    Objections, regarding the application of Johnson Matthey, Inc., for 
    registration as an importer of raw opium and concentrate of poppy 
    straw, Schedule II controlled substances, is published pursuant to 21 
    CFR 1301.34. On April 9, 1999, DEA published a notice in the Federal 
    Register, 64 FR 17,415 (DEA 1999), stating that Johnson Matthey has 
    applied to be registered as an importer of raw opium and concentrate of 
    poppy straw.
        Both Noramco of Delaware, Inc., and Mallinckrodt, Inc., timely 
    requested a hearing in this matter. On September 20, 1999, all parties 
    filed prehearing statements. Notice is hereby given that a hearing will 
    be conducted pursuant to the provisions of 21 U.S.C. 952(a), 958; 21 
    CFR 1301.34.
    
    Hearing Date
    
        The hearing will begin at 9:30 a.m. on January 5, 2000, and will be 
    held at the Drug Enforcement Administration Headquarters, 600 Army Navy 
    Drive, Hearing Room, Room E-2103, Arlington, Virginia. The hearing will 
    be closed to the public, except (a) to the parties, and (b) to those 
    persons who have a right to participate and have requested a hearing or 
    entered a notice of appearance pursuant 21 CFR 1301.34.
    
    Notice of Appearance
    
        Any person entitled to participate in this hearing pursuant to 21 
    CFR 1301.34, and desiring to do so, may participate by filing a notice 
    of intention to participate in accordance with 21 CFR 1301.43, in 
    triplicate, with the Hearing Clerk, Office of Administrative Law 
    Judges, Drug Enforcement Administration, Washington, DC 20537, within 
    30 days of publication of this notice in the Federal Register. Each 
    notice of appearance must be in the form prescribed in 21 CFR 1316.48. 
    Johnson Matthey, DEA Office of Chief Counsel, Mallinckrodt, and Noramco 
    need not file a notice of intention to participate.
    
    FOR FURTHER INFORMATION CONTACT: Helen Farmer, Hearing Clerk, Drug 
    Enforcement Administration, Washington, DC 20537; Telephone (202) 307-
    8188.
    
    Summary of Comments and Objections
    
    Mallinckrodt's Comments
    
        Mallinckrodt, a registered importer of raw opium and poppy straw 
    concentrate, intends to show that Johnson Matthey lacks a sufficient 
    commitment to comply with DEA regulations; Johnson Matthey's 
    registration will undermine the ability of U.S. importers to comply 
    with the 80/20 sourcing rule; Johnson Matthey's lack of technical 
    expertise regarding the importation of narcotic raw materials (NRMs) 
    and the use of NRMs during manufacturing could result in shortage of 
    NRMs; Johnson Matthey's processing inefficiencies could lead to 
    increases in opium cultivation in violation of international policy; 
    and as Johnson Matthey has no intention of using the registration, the 
    potential registration constitutes an unnecessary administrative 
    burden.
    
    Noramco's Comments
    
        Noramco, a registered importer of NRMs, intends to show that 
    Johnson Matthey's capability to maintain effective controls required by 
    an importer of NRMs is questionable given its past record in the area 
    of controlled substances; Johnson Matthey's registration is likely to 
    weaken U.S. ability to contain the rapid increase in the price of NRMs; 
    Johnson Matthey's plans for importation may be inconsistent with DEA 
    restrictions on sourcing or may place an unfair burden on existing 
    suppliers; Johnson Matthey's planned use of the NRMs will excerbate a 
    shortage of NRMs; and Johnson Matthey's planned use of NRMs may 
    adversely affect the industry's total cost of production.
    
        Dated: November 29, 1999.
    Richard A. Fiano,
    Acting Deputy Administrator, Drug Enforcement Administration.
    [FR Doc. 99-31437 Filed 12-2-99; 8:45 am]
    BILLING CODE 4410-09-M
    
    
    

Document Information

Published:
12/03/1999
Department:
Drug Enforcement Administration
Entry Type:
Notice
Document Number:
99-31437
Pages:
67936-67936 (1 pages)
Docket Numbers:
Docket No. 99-27
PDF File:
99-31437.pdf